Drug Profile
Research programme: small molecule nuclein acid-based antibody drug conjugates - F-star Therapeutics/Unknown organisation
Alternative Names: SB 11325; SB 11326; SB 11345; SB 11396Latest Information Update: 09 Mar 2023
Price :
$50
*
At a glance
- Originator Spring Bank Pharmaceuticals; Unknown
- Developer F-star Therapeutics; Unknown
- Class Antibodies; Antineoplastics; Immunoconjugates
- Mechanism of Action MPYS protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 09 Mar 2023 F-star Therapeutics has been acquired by invoX Pharma
- 28 Sep 2022 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 20 Nov 2020 Spring Bank Pharmaceuticals has merged with F-star to form F-star Therapeutics